Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Urticaria

    Urticaria Content

    Allergic Conditions, Urticaria
    Luis Felipe Ensina, leading innovation in allergy and immunology
    Global Impact, Brazilian Roots: Prof. Ensina’s journey leading innovation in allergy and immunology

    A globally recognized allergologist specializing in urticaria, drug allergies, and angioedema, Professor Luis FC Ensina has significantly advanced clinical care, research, and education. As a Professor at the Federal University of São Paulo and coordinator of its specialized outpatient clinic, he leads Alergoalpha, a Center of Excellence for UCARE, ACARE, and ADCARE, where he has overseen over 20 clinical trials and authored more than 100 publications. A founder of the Brazilian Urticaria Network (RUBRA) and co-author of international urticaria guidelines, he has played a pivotal role in shaping global standards for allergy care. Active in organizations such as GA2LEN, AAAAI, and EAACI, he highlights the transformative potential of emerging therapies, gene therapy, and artificial intelligence to redefine allergy and immunology practice worldwide.

    Urticaria
    Honouring Prof. Marcus Maurer

    We are deeply saddened to learn that Prof. Marcus Maurer, a highly esteemed expert and valued member of the touchIMMUNOLOGY faculty, has been missing for several weeks following a hiking expedition in the mountains.

    Allergic Conditions, Dermatological Conditions, Immunology, Haematological Disorders, Urticaria
    Watch Time: 52 mins
    touchPANEL DISCUSSION
    Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
    CE/CME ACCREDITED Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose Translations available:

    Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

    Learning objectives
    Learning Objectives
    • Describe the signs, symptoms and diagnostic pathway for systemic mastocytosis
    • Explain how to apply personalized treatment strategies using a multidisciplinary approach to effectively manage systemic mastocytosis
    • Recall the latest data for new and emerging treatments for systemic mastocytosis and evaluate their potential impact on the clinical management of systemic mastocytosis in the future
    Urticaria
    Developed by Touch
    Urticarial vasculitis: diagnosis, clinical presentation & treatment paradigm – a UCARE study: Pavel Kolkhir, EAACI 2023
    Watch Time: 6 mins

    Urticarial vasculitis is a rare inflammation of the blood vessels which results in clinical manifestations resembling urticaria with the addition of wheals, there remain no direct treatment options and management involves antihistamines, NSAIDS and ibuprofen to treat the cutaneous manifestations. We were delighted to speak to Dr. Pavel Kolkhir (Charité-Universitätsmedizin Berlin, Berlin, Germany) around the […]

    Allergic Conditions, Urticaria
    Developed by Touch
    CRUSE® app, for the management of chronic spontaneous urticaria: Marcus Maurer
    Watch Time: 3 mins

    The CRUSE® app has been developed for the self-management of chronic spontaneous urticaria (CSU), and to help physicians develop personalised treatment strategies for patients. touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the availability, functions, and clinical implications of the app. Questions: Please could you […]

    Urticaria
    Developed by Touch
    Remibrutinib in chronic spontaneous urticaria patients: phase 3b extension trial: Marcus Maurer, EAACI 2023
    Watch Time: 3 mins

    Phase 2 results of remibrutinib for chronic spontaneous urticaria (CSU) show a fast and sustained response to treatment. While the phase 3b trial is ongoing, touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the rationale for studying remibrutinib in relation to CSU and the ongoing […]

    In Partnership with...
    Useful Links:
    About us Society Partners Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2025 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchIMMUNOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup